| MVP方案动脉灌注治疗非小细胞肺癌的临床研究 |
| |
| 引用本文： | 曹强,荣阳.MVP方案动脉灌注治疗非小细胞肺癌的临床研究[J].中国现代医生,2012,50(3):148-149,151. |
| |
| 作者姓名： | 曹强 荣阳 |
| |
| 作者单位： | 1. 辽宁省辽阳市第三人民医院放射介入科,辽宁辽阳,111000
2. 中国医科大学辽阳中心医院放射科,辽宁辽阳,111000 |
| |
| 摘 要： | 目的 观察MVP方案动脉灌注治疗非小细胞肺癌（NSCLC）的临床疗效。方法 选择2007年1月-2010年12月收治的经病理证实的NSCLC患者100例采用MVP方案【丝裂霉素（MMC）＋长春地辛（VDS）＋顺铂（DDP）】、支气管动脉灌注（BAI）治疗，BAI治疗每例至少2次。结果 本组总有效率84％，总体生存期13个月，中位生存期平均】6个月，一年生存率78％。多数患者治疗后疼痛减轻、肿块缩小、通气改善、血痰消失或减少、肺不张复张。多、中血供型肺癌明显高于少血供型肺癌（P〈0．01）。结论 MVP方案、BAI治疗NSCLC效果确切，值得临床推广应用。
|
| 关 键 词： | 化疗 动脉灌注 非小细胞肺癌 介入 |
The clinical research of MVP scheme artery perfusion in treatment of non-small-cell lung cancer |
| |
| Authors: | CAO Qiang RONG Yang |
| |
| Institution: | 1.Department of Radiology and Intervention,the Third Hospital of Liaoyang in Liaoning Province,Liaoyang 111000,China;2.Department of Radiology,Liaoyang Center Hospital Affiliated China Medical University,Liaoyang 111000,China |
| |
| Abstract: | Objective To observe the effect of MVP scheme artery perfusion treatment on the non-small-cell lung cancer(NSCLC) curative.Methods All of 100 patients with NSCLC pathologically proved from Jan 2007 to Nov 2010 were given MVP Mitomycin(MMC) + Vindesine(VDS) + Cisplatin(DDP)] and the bronchial arterial perfusion(BAI)(each patient at least twice).Results The total effective rate was 84%,total survival time was 13 months,median survival time was 16 months,and one-year survival rate was 78%.Most patients pain mitigated,mass narrowed,improve ventilation,blood sputum disappear or reduce,ventilation improved significantly.In the more blood supply for lung cancer was significantly higher than the less blood supply for lung cancer(P<0.01).Conclusion MVP plan BAI has a good result in the treatment of NSCLC. |
| |
| Keywords: | Chemotherapy Artery perfusion Non-small cell lung cancer Iintervention |
| 本文献已被 CNKI 维普 万方数据 等数据库收录！ |
|
